Lv12
50 积分 2024-01-18 加入
[Expert consensus on the diagnosis and treatment of anticancer drug-induced interstitial lung disease]
3天前
已完结
Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
7天前
已完结
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
11天前
已完结
Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature
15天前
已完结
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
15天前
已完结
Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology
15天前
已完结
Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma
15天前
已完结
Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancer
15天前
已完结
Problematic crossovers in cancer drug trials
3个月前
已完结
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer
4个月前
已完结
皖公网安备34019202002308
